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ﬁed the study population into groups by their oral hypoglycemic agents, and further 
analyzed the hazard ratio of myocardial infarction (MI) in different add-on medication 
and the survival of cardiovascular diseases between add-on TZDs group and non-TZD 
group. NMB regression model was used to estimate the cost-effectiveness difference 
on patients who used TZDs versus non-TZD users. RESULTS: The Cox proportional 
hazard model analysis demonstrated that sulfonylurea +rosiglitazone group had a 
higher risk of hospitalization for cardiovascular diseases comparing to add-on met-
formin group (HR 1.48, 95% CI: 1.21–1.80); As to the cost-effectiveness analysis: 1) 
Comparing to sulfonylurea+metformin group, the average annual medication cost 
(AAMC) per capita of sulfonylurea+rosiglitazone group increased NT$12,944, but the 
average days for hospitalization decreased 0.12 day; while the AAMC of sulfonylurea 
+pioglitazone group increased NT$10,329, but the average days for hospitalization 
decreased 0.22 day. 2) Comparing to metformin+sulfonylurea group, the AAMC of 
metformin+rosiglitazone group increased NT$11,486 dollars, but the average day for 
hospitalization decreased 0.09 day; while metformin+rosiglitazone group increased 
NT$11267, but the average days for hospitalization decreased 0.18 day. CONCLU-
SIONS: Our results demonstrated that sulfonylurea + rosiglitazone group had a higher 
risk of hospitalization for cardiovascular diseases versus metformin group with TZD 
add-on treatment (HR 1.48, 95% CI: 1.21–1.80), and per capita AAMC was higher 
(NT$12944 increment) which was not justiﬁed in the decrease of 0.12 hospitalization 
days 0.12. As for other metformin add-on groups, the increased medication cost was 
also not justiﬁed.
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COST-EFFECTIVENESS ANALYSIS OF THE DIABETES MEDICATIONS IN 
MEDICARE WITH SAS
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OBJECTIVES: The primary purpose of this study is to estimate the cost efﬁciency of 
the diabetes medications in Medicare in the year 2005 and the year 2006 to investigate 
the impact of Medicare, Part D. METHODS: In this study, several data sets from the 
Medical Expenditure Panel Survey are used as collected by the Agency for Healthcare 
Research and Quality. The data sets provide information on the prescribed drug, 
demography, ofﬁce-based visits, outpatients and inpatients for the years 2005 and 
2006.The analysis is based on the Medicare payments for anti-diabetic drugs, without 
considering the drug forms and cost-efﬁciency as measured by the Medicare payment 
amounts for ofﬁce-based visits, inpatients or outpatients. Statistics methods used 
include One-Way Frequencies, Summary Statistics, Box and Whisker Plots, Linear 
Multiple Regression and Spearman’s rank correlation. SAS SQL and some SAS func-
tions such as the MDY function and 0–1 indicator functions are utilized to preprocess 
the data. RESULTS: Results demonstrate that metformin users have fewer physician 
visits, lab tests and shorter length of stay in the hospital and it has a negative relation-
ship with the former two factors. Insulin, metformin and its combination with glybu-
ride are signiﬁcant to predict the frequencies of doctor ofﬁce visits, lab tests and length 
of stay. From the year 2005 to the year 2006, insulin and metformin users reduce 
their frequencies of physician visits and lab tests as well as days in the hospital. 
CONCLUSIONS: Among the diabetes medications in Medicare, metformin is the most 
cost-effective drug due to the fewest Medicare expenditures for ofﬁce-based visits, 
inpatients and outpatients with spending one dollar on the drug. In 2006, with Medi-
care part D, metformin becomes more efﬁcient, while insulin becomes more effective 
at the cost of an increased price .Therefore, it is recommended to prescribe metformin 
for the Medicare diabetic beneﬁciaries.
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OBJECTIVES: The NICE study was a ﬁve-year, open-label, randomized controlled 
trial that compared cardiovascular outcomes in Japanese type 2 diabetes patients 
intensively treated with human insulin (HI) or insulin aspart (IAsp). Using data from 
the NICE study, the cost-effectiveness of IAsp versus HI was evaluated from the 
perspective of a third-party health care payer over a ten-year time horizon (ﬁve years 
within-trial observation and ﬁve years post-trial extrapolation). METHODS: A dis-
crete event simulation model was developed in Microsoft Excel® to assess the within-
trial cost-effectiveness and make longer-term clinical projections in patients treated 
with regular human insulin or insulin aspart. Life expectancy, quality-adjusted life 
expectancy, cardiovascular event rates and costs were evaluated over a ten-year time 
horizon. Event costs were calculated from hospital receipt data supplied by the Japa-
nese Medical Data Center. Annual insulin costs were obtained from the NICE study. 
Other pharmacy costs were assumed to be the same in both treatment arms and were 
not captured in the analysis. All costs were expressed in 2008 Japanese Yen (JPY) and 
future costs and clinical beneﬁts were discounted at 3% annually. Sensitivity analyses 
were performed. RESULTS: Compared with HI, IAsp was dominant (life- and cost-
saving) over a ten-year time horizon. IAsp was associated with an improvement in 
discounted life expectancy of 0.056 years and an improvement of 0.085 quality-
adjusted life years (QALYs) versus HI. Insulin aspart was projected to save an average 
of JPY 290,719 per patient. As in the exclusively in-trial analysis, pharmacy costs were 
found to be higher (difference JPY 129,408), but were again more than offset by cost 
savings resulting from a reduced incidence of cardiovascular complications, a differ-
ence of JPY -420,126. CONCLUSIONS: In a Japanese type 2 diabetes population, 
prescribing rapid-acting insulin aspart signiﬁcantly reduced cardiovascular complica-
tions, resulting in increased quality of life and decreased costs compared with human 
insulin.
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OBJECTIVES: To estimate the economic and health consequences of the use of DPP4 
plus metformin in the treatment of patients with type 2 diabetes in Mexico METHODS: 
A cost-effectiveness analysis was done using a discrete event model to simulate the 
behavior of a hypothetic population with 40 years follow-up, to evaluate the number 
of complications (ischemic heart disease, myocardial infarction, congestive heart 
failure, stroke, amputation, retinopathy and ESRD), their costs and quality-adjusted 
life years (QALY’s); and the expected cost with the use of metformin+DPP4 (MDPP4), 
metformin+sulfonylureas (MSU), metformin+thiazolidinediones (MTZ) and metfor-
min (MF). The demographic and clinical background of the patients used in the model 
was obtained based on expert panel opinions (11 physicians). A systematic literature 
review was performed to get information on effectiveness (reduction in HbA1c level 
and related complications risk as reported in the UKPDS) and quality of life. Utiliza-
tion of health care resources was collected from clinical ﬁles (n = 182) at Hospital 
General Zona n° 8 of the Mexican Social Security Institute. Private costs of complica-
tion treatments were obtained from institutional sources applying a conversion ratio 
of 2.46 times as referred in the literature. Drug prices as based on private reference 
prices (ﬁxed by the regulatory authorities). All costs are expressed in 2009 US$. 
Probabilistic sensitivity analysis was performed (1000 Monte Carlo iterations) and 
acceptability curves were constructed. Both cost and QALY’s were discounted at 5% 
RESULTS: The expected treatment cost and QALY’s for MF is $250,213.26 and 
12.97 respectively; MSU $255,910.09 and 13.26; MTZ $255,177.26 and 13.27; 
MDPP4 $245,055.52 and 13.41. The probability of being cost-effective at a threshold 
of $30,621.30 (equivalent to 3 times the Mexican GDP per-capita) with MSU is 
0.543 CI95%(0.512–0.574); MTZ 0.593 CI95%(0.563–0.623); and MDPP4 
0.867 CI95%(0.846–0.888) CONCLUSIONS: The scheme based on metformin+DPP4 
presents the best cost effectiveness ratio against metformin+sulfonylureas or 
metformin+thiazolidinediones.
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OBJECTIVES: Diabetic Peripheral Neuropathic Pain (DPNP) is a chronic neuropathic 
condition that signiﬁcantly affects both health-related quality of life and functional 
status, causing depression and disabilities, increased health care utilization and high 
costs. We aimed to perform an economic evaluation of three recommended ﬁrst-line 
medications for DPNP. METHODS: The analysis was conducted using a three-month 
decision model, which compares duloxetine 60mg once daily (DUL), gabapentin 
600mg 3-times daily (GAB) and pregabalin 150mg twice daily (PRE) for patients with 
DPNP and moderate to severe pain, under the perspective of public health care system 
in Mexico. Efﬁcacy rates were gathered from published literature. Adherence (based 
in number of daily doses needed) and adverse effects (AE) rates were incorporated 
into the model. Direct medical costs included drug acquisition and additional medical 
consultation due to lack of efﬁcacy (poor pain relief) or intolerable AE. Unit costs 
were taken from local public tariffs. All costs were calculated in 2009 Mexican Pesos 
(MXP) and then expressed in USD. Proportion of patients with Good Pain Relief 
(GPR) and expected quality-adjusted life years (QALY) by patient was assessed. 
RESULTS: Branded GAB and PRE were both dominated by generic GAB and DUL. 
Compared to branded GAB and PRE, DUL leads to savings of 98 and 129 USD per 
patient, respectively. The incremental cost per QALY gained with DUL used instead 
of generic GAB is 8821 USD. This amount is similar to the estimated gross domestic 
product per capita in Mexico during 2008 year. DUL was cost-effective compared to 
generic GAB in about 83% of the samples during a second-order Monte Carlo simula-
tion. CONCLUSIONS: DUL had lower costs and better health outcomes when com-
pared to both branded GAB and PRE. According to the recommendations stated by 
the World Health Organization, DUL can be seen as a cost-effective intervention 
compared to generic GAB.
PDB34
A COST-MINIMIZATION ANALYSIS FOR TYPE 2 DIABETES WITH 
INSULIN GLARGINE COMPARED TO INSULIN DETERMIR IN A BASAL 
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OBJECTIVES: To compare the treatment costs in China of 2 basal insulin analogues, 
glargine and determir, when used in combination with oral antidiabetic drugs(basal 
supported oral therapy) in insulin naïve type 2 diabetes patients. METHODS: The 
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Rosenstock study and other two RCTs compared Glargine to Determir showed 
Glargine and Determir has not difference in HbA1c control and hypoglycemia rate 
for the patient with type 2 diabetes. Based on the Rosenstock study, cost-minimization 
study was performed. Mean daily detemir dose was higher (0.78 U/kg [0.52 with once 
daily dosing, 1.00 U/kg with twice daily dosing]) than glargine (0.44 IU/kg). Annual 
direct cost was estimated from the perspective of the health insurance in China. The 
time horizon was one year of treatment. The price was referred to Price in 2008. The 
currency is Yuan. The cost of insulin medication (glargine or determir) and consum-
able items (needles, blood glucose test strips) was collected as the direct costs. Univari-
ate sensitivity analysis on resource use and unit costs around base case parameter 
values was performed to test the robustness of the base case results RESULTS: Insulin 
glargine was associated with 40.77% (8949.05RMB per year)cost saving compared 
to insulin determir, for an equivalent level of metabolic control , although the price 
of determir is lower in China. Univariate sensitivity analysis on resource use and prices 
in Determir has been performed and conﬁrmed the robustness of the results in favour 
of insulin glargine in China. The current study ﬁndings are consistent with the direc-
tion and magnitude of cost saving reported in Spain, Hungary, Argentina, Germany 
and UK. CONCLUSIONS: Insulin glargine was cost saving compared to insulin 
determir in China. The information is importance for health care providers who are 
considering the total budget for the type 2 DM patient with basal insulin.
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OBJECTIVES: To determine the cost-effectiveness ratio of adding saxagliptin to 
metformin therapy (SAXA+MET) compared to adding sulfonylureas (SULF+MET), in 
patients with type 2 diabetes mellitus (DM2) who have failed to achieve adequate 
glycemic control with metformin. METHODS: A discrete event simulation model 
(Cardiff Long term cost-utility model) based on UKPDS 68 with a ﬁxed time increase 
was used to simulate disease progression and to obtain an estimate of the treatment’s 
economic and health consequences in DM2 patients. The clinical efﬁcacy parameters 
for saxagliptin were obtained from the literature; drug acquisition costs, adverse 
effects (AEs) and microvascular and macrovascular complications were taken into 
account. Costs were expressed in United States dollars (2009), with an annual 3.5% 
discount. The time horizon was 20 years. RESULTS: A lower number of non-fatal 
events was found for the SAXA+MET-treated group versus the SULF+MET-treated 
group. Additionally, the model predicted a lower number of fatal events due to mac-
rovascular (146 vs. 151) and microvascular (17.7 vs. 17.9) events for the SAXA+MET-
treated group vs. the SULF+MET-treated group. The total cost of the SAXA+MET 
cohort was 14% higher than that of the SULF+MET cohort. Treatment with 
SAXA+MET resulted in a higher number of QALYs (9,392 vs. 9,172) and LYGs 
(20,898 vs. 20,797) than treatment with SULF+MET; the additional cost per QALY 
and LY gained was US$6,691 and US$ 14,656 respectively. CONCLUSIONS: Con-
sidering the GDP per capita in Argentina, results suggest that the addition of saxaglip-
tin to metformin therapy compared to the addition of sulfonylureas would yield 
acceptable cost-effectiveness ratios in DM2 patients in Argentina.
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OBJECTIVES: To assess the impact of pDPN/PHN-related health impairment on 
LOPT in patients treated with chronic pDPN/PHN. METHODS: Using data from 777 
employed adults with ≥3 months of pDPN/PHN and receiving pain medications, the 
effect of pDPN/PHN-related impairment on LOPT was estimated by: 1) single equa-
tion probit models (SEPM) assuming pain severity was exogenous, adjusting for 
respondents’ demographics, depression, anxiety, pain duration, type of pain, social 
isolation (felt alone/didn’t want to go out) and psychological distress (felt older/sleep 
difﬁculties); and 2) seemingly unrelated bivariate probit models (SUBPM), hypothesiz-
ing pain severity was endogenous and considering the same explanatory variables from 
the SEPM as instrumental variables (IVs). Pain severity was measured using a rating 
scale ranging from 0 (“no pain”) to 10 (“pain as bad as you can imagine”). RESULTS: 
Thirty percent of respondents reported LOPT. Compared to respondents without 
LOPT, respondents with LOPT were younger, male, and had more moderate/severe 
pain (all p < 0.001). Pain severity appears signiﬁcantly related with social isolation 
and psychological distress. Its relationship with LOPT appears only signiﬁcant when 
the latter variables were neglected in the SEPM or when they were used as IVs in the 
SUBPM. Marginal effects indicated that, compared to respondents with pain severity 
< 4, those with pain severity ≥4 were 19.3% more likely to incur LOPT when using 
the SEPM and, 29.5% more likely when using the SUBPM (all p < 0.001). Model 
speciﬁcation tests suggested that pain severity to be truly endogenous and that all IVs 
jointly had sufﬁcient explanatory power (all p < 0.001). CONCLUSIONS: Pain sever-
ity has a signiﬁcant impact on LOPT. The degree of this impact depends on ones’ 
ideas about how this impact is mediated by respondents’ social isolation and psycho-
logical distress. Alternative IVs for adjusting endogeneity bias of pain severity are 
worth exploring.
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OBJECTIVES: The purpose of this study is to consider the extent to which estimates 
of the impact of diabetes on employment status, absenteeism and presenteeism varies 
between China and Japan. METHODS: Data from the 2008 and 2009 National 
Health and Wellness Surveys undertaken in Japan and urban China were used to 
estimate a logistic employment status model and ordered probit regression analyses 
of the determinants of absenteeism and presenteeism for those employed full-time, 
part-time or self employed. Absenteeism was determined by respondents indicating 
time off due to ill health in the past seven days; presenteeism was determined by 
respondents assessing the extent to which workplace productivity was impacted by 
their health status in the same time period. Apart from diabetic status the models 
included demographic and socio-economic characteristics, the Charlson Comorbidity 
Index, together with health risk factors and controls for absenteeism experience and 
diagnosed diabetes. RESULTS: In both China and Japan a diagnosis of diabetes was 
found to have a signiﬁcant (1% level) negative impact on employment status (odds 
ratios 0.540 and 0.796 respectively). The results for absenteeism point once again to 
the signiﬁcant (at 1% level) positive impact of diabetes on higher rates of absenteeism 
with odds ratios of 3.057 for China but only 1.410 respectively for Japan. In the case 
of presenteeism the impact of diabetes is still signiﬁcant (1% level) in the case of China, 
but less so for Japan (odds ratios 2.102 and 1.179 respectively). CONCLUSIONS: 
The presence of diabetes has a signiﬁcant and negative impact on workforce status as 
well as on absenteeism in China and Japan. Both countries show similar impacts, 
although in Japan the impact on presenteeism is less marked.
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OBJECTIVES: The purpose of this study is to consider the extent to which estimates 
of the impact of diabetes on presenteeism can vary between major industrial countries 
and to assess the relative contribution of absenteeism, socio-demographic and health 
risk factors. METHODS: Data from the 2008 National Health and Wellness Survey, 
a national survey of ﬁve EU countries (the UK, France Spain, Germany and Italy) were 
used to estimate an ordered probit regression analysis of the determinants of presentee-
ism for those employed full-time, part-time or self employed. Presenteeism was deter-
mined by respondents assessing the extent to which workplace productivity was 
impacted by their health status on a 10-point scale. The model includes health risk 
factors (BMI, alcohol use, smoking), the Charlson Comorbidity Index (CCI) along 
with controls for absenteeism experience and diagnosed diabetes. RESULTS: Absen-
teeism, the percentage of time lost in the previous seven days, was the dominant factor 
impacting presenteeism for all countries (odds ratios 16.17 Germany to 9.23 Italy). 
With the exception of Spain, obesity and morbid obesity had a positive and signiﬁcant 
impact with odds ratios in the range 1.33 – 1.04 and 2.08 – 1.60 respectively. The 
presence of diabetes was signiﬁcant for all countries with odds ratios ranging from 
1.29 (Italy) to 1.77 ( Spain). Replacing diabetes with the CCI resulted in signiﬁcant 
odds ratios in the range 1.33 (Germany) to 1.17 ( UK). CONCLUSIONS: The presence 
of diabetes has a signiﬁcant and negative impact on workplace presenteeism. The 
impact of diabetes is of a similar order of magnitude to the presence of obesity and 
morbid obesity.
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OBJECTIVES: Associations between type 2 diabetic patients’ beliefs and expectations 
about their illness and medication adherence were determined. METHODS: A cross-
sectional self-administered written survey of type 2 diabetes patients was conducted 
in an outpatient pharmacy, at a primary care clinic afﬁliated with a hospital serving 
an urban population. Study inclusion criteria were being 18 years or older, diagnosed 
with type 2 diabetes at least 6 months prior to the time of the survey, and taking oral 
anti-diabetic medication. Exclusion criteria were use of insulin or not being able to 
read and write in English. The survey included the Brief Illness Perception Question-
naire (B-IPQ) to assess individuals’ illness beliefs and the Morisky 8-item Medication 
Adherence Scale to collect self-reported adherence. Chi-square tests of association and 
Pearson correlation analysis were used to assess whether illness beliefs were associated 
with adherence. RESULTS: Two-hundred and ﬁve completed responses were obtained 
from 354 individuals who satisﬁed inclusion and exclusion criteria, for a response rate 
of 58%. The sample was 50% Caucasian, 50% African-American, 63% female and 
72% had annual household income of less than $25,000. A majority (56%) reported 
